Introduction. The prevalence of bacterial vaginosis (BV) in the population ranges from 12 to 80% and depends on the cohort of examined women. Of the total confirmed cases, 37-40% are pregnant women.Aim. To assess the effectiveness of the treatment of bacterial vaginosis (BV) in pregnant women.Materials and methods. The study included 43 women at 22 to 30 weeks' gestation, divided into two groups: the treatment group consisted of 30 pregnant women diagnosed with BV, the control group comprised 13 pregnant women with normal vaginal microbiocenosis. To determine the antimicrobial activity of vaginal epithelium, samples of vaginal discharge were examined. The treatment was carried out using clindamycin according to the following regimen: 100 mg intravaginally per day at bedtime for 3 days.Results. The study results showed that the highest activity of antimicrobial peptides (AMP) was found in the group of healthy pregnant women, which accounted for 79.1%. In pregnant women with BV, the level of antimicrobial activity significantly decreased as compared with the group of healthy pregnant women as the severity of the disease increased, amounting to 44.5% in women with mild BV, 36.4% in women with moderate BV and 33.6% in women with severe BV. The level of antimicrobial activity in the group of pregnant women with BV, who received treatment with clindamycin significantly increased by almost two times from the baseline values and amounted to 86.1% in women with mild BV, 78.5% in women with moderate BV and 76.9% in women with severe BV.Conclusion. The production of endogenous antibiotics, AMP, provides adequate protection against infectious agents. After a  course of therapy with clindamycin 100 mg intravaginally at bedtime for 3 days, the AMP level normalized 2 weeks after treatment.

Introduction. Latent iron deficiency, which has a high prevalence among women of childbearing age, most often, in the absence of therapy, progresses in pregnant women into manifest iron deficiency, manifested by clinical symptoms of anemia and associated with a complicated course of pregnancy, childbirth, the postpartum period, unfavorable outcomes of newborns. The above justifies the need for correction of iron deficiency at the preconception period.Aim. To evaluate the effectiveness of therapy latent iron deficiency at the stage of preconception period.Materials and methods. The study included 32 women at the stage of pregnancy planning with latent iron deficiency. All women taking the drug Ferretab 1 pill per day for 1 month. The level of blood parameters was assessed at 3 months before the intended conception, in the I, II and III trimesters of pregnancy, in the 3rd day after delivery. In newborns, the indicators of a clinical blood test were evaluated on the 2nd day after birth. We evaluated such indicators as the level of hemoglobin, erythrocytes, hematocrit, the average content of hemoglobin in erythrocytes, serum ferritin, serum iron, transferrin.Results. Evaluation of laboratory data in the course of the study confirmed the effectiveness of the use the complex drug Ferretab. Patients already at the first visit to the doctor during pregnancy had a positive trend and a significant increase in the level of hematological parameters.Conclusions. Oral administration of the complex drug Ferretab showed high efficiency in the treatment of latent iron deficiency at the stage of preconception period, significantly increasing the levels of hematological parameters, good tolerance and a small number of side effects, contribute to the high adherence of patients to therapy, which allows achieving significant clinical results.

No abstract

Introduction. According to researchers from different countries, the incidence of neonatal herpes varies noticeably.   Objective. Optimization of pre-gravid preparation of women with chronic recurrent genital herpes to reduce pregnancy complications and improve perinatal outcomes.   Мaterials and methods. The study included 58 women with confirmed chronic recurrent genital herpes. Two groups were formed, the main group included 30 women receiving pre-gravid preparation, complex treatment with antiviral and immunomodulatory drugs, the comparison group was represented by 28 women receiving pre-gravid preparation and only antiviral drug. Evaluation of the effectiveness of the treatment of chronic genital herpes and the benefits of pre-gravid preparation were carried out by assessing clinical manifestations, determining the immune status, analyzing the characteristics of the course of pregnancy, childbirth, and perinatal outcomes.   Results. As a result of the study, the available data confirm the feasibility of using complex therapy in the treatment of chronic recurrent genital herpes in combination with pre-gravid preparation.   Conclusion. Pre-gravid preparation and specific treatment of women with chronic recurrent genital herpes improve the clinical status of patients, increase the interrecurrent period, reduce the severity of prodromal symptoms, the duration and intensity of relapses of the disease, and contribute more favorable course of pregnancy and improvement perinatal outcomes.

This review focuses on the causes and consequences of nutritional deficiencies in the pregnant woman’s diet, as well as on the possibilities of its supplementation. It has been shown that inadequate intake of vitamins and minerals during pregnancy is accompanied by a lack of nutrient supply to the fetus, which can cause growth retardation, low birth weight and other obstetric and perinatal complications.According to the analysed guidelines and recommendations, the body’s need for vitamins and minerals increases at least twice as much during pregnancy. Adverse effects of the environment, a number of gastrointestinal and liver diseases, chronic diseases, antibiotic therapy, etc. increase this need.However, adequate nutritional support of the fetus is the result of several steps. These include the frequency of maternal food intake, the availability of nutrients in the food and the ability of the placenta to transport substrates effectively to the fetus.The most recommended vitamin for consumption in pregnancy is folic acid, alone or in combination with other B vitamins, as its deficiency leads to birth defects in the child.The authors of this review have reviewed a number of large studies conducted over the past decade that recommend iron and folic acid for pregnant women, regardless of dietary intake, as they have proven beneficial effects on the course and outcome of pregnancy. Folic acid, according to current recommendations, must be prescribed to every pregnant woman in the form of 400 mcg tablets daily regardless of her diet. Other most important and necessary vitamins for pregnant women are: vitamins A, C, D, E, K, B1, B2, B6, B12, PP, pantothenic acid, biotin.